MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells

Qingling Yang; Yangyang Wang; Xiaohui Lu; Zunlan Zhao; Lihua Zhu; Sulian Chen; Qiong Wu; Changjie Chen; Zhiwei Wang

doi:10.18632/oncotarget.3065

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells

Qingling Yang, Yangyang Wang, Xiaohui Lu, Zunlan Zhao, Lihua Zhu, Sulian Chen, Qiong Wu, Changjie Chen _ and Zhiwei Wang

PDF | HTML | How to cite

Oncotarget. 2015; 6:3268-3279. https://doi.org/10.18632/oncotarget.3065

Metrics: PDF 2795 views | HTML 4016 views | ?

Abstract

Qingling Yang1,*, Yangyang Wang2,*, Xiaohui Lu2,*, Zunlan Zhao2, Lihua Zhu2, Sulian Chen1, Qiong Wu3, Changjie Chen1 and Zhiwei Wang4

1 Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui, China

2 Clinical Testing and Diagnose Experimental Center of Bengbu Medical College, Anhui, China

3 Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

4 Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

* These authors contributed equally to this work

Correspondence:

Changjie Chen, email:

Zhiwei Wang, email:

Keywords: Paclitaxel, miR-125b, EMT, invasion, breast cancer

Received: November 20, 2014 Accepted: December 14, 2014 Published: December 18, 2014

Abstract

Emerging evidence has demonstrated that microRNAs (miRNA) play a critical role in chemotherapy-induced epithelial-mesenchymal transition (EMT) in breast cancer. However, the underlying mechanism of chemotherapy-mediated EMT has not been fully understood. To address this concern, we explored the role of miR-125b in regulation of EMT in stable paclitaxel-resistant (PR) breast cancer cells, namely MCF-7 PR and SKBR3 PR, which have displayed mesenchymal features. Our results illustrated that miR-125b was significantly downregulated in PR cells. Moreover, ectopic expression of miR-125b by its mimics reversed the phenotype of EMT in PR cells. Furthermore, we found that miR-125b governed PR-mediate EMT partly due to governing its target Sema4C. More importantly, overexpression of miR-125b or depletion of Sema4C sensitized PR cells to paclitaxel. These findings suggest that up-regulation of miR-125b or targeting Sema4C could serve as novel approaches to reverse chemotherapy resistance in breast cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3065

Publication Alerts

Research Papers:

MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells

Abstract